MYRIAD GENETICS INC

MYRIAD GENETICS INC (MYGN) is a publicly traded US company. Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

The company reports trailing twelve-month revenue of $193.50M and net loss of $34.10M.

Key metrics include a return on equity of -10.1%, a debt-to-equity ratio of 1.00.

Investors tracking MYGN can follow price movements, analyst estimates, and fundamental changes directly through FINOTAUR's research tools.